What does Valion Bio, Inc. do?

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an…

What is Valion Bio, Inc.'s P/E and P/B ratio?

Valion Bio, Inc. has a P/E ratio of -0.0 and a P/B ratio of 0.44.

What is Valion Bio, Inc.'s debt-to-equity ratio?

Valion Bio, Inc. has a debt-to-equity ratio of 4.10.

How much does Valion Bio, Inc. owe compared with what it owns?

Valion Bio, Inc. owes $0.87 for every $1 it owns (balance sheet Jun 2026), which is high.

Does Valion Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

Yes. Valion Bio, Inc. has 1 active red flag (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 20 Mar 2026). It has no yellow flags.

Where can I read the latest news about Valion Bio, Inc.?

Recent headlines about Valion Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Valion Bio, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Valion Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

Valion Bio, Inc.

Q: What is Valion Bio, Inc.'s Positivity rank?

Valion Bio, Inc. is ranked #5,295 of 6,774 companies globally and #2,854 of 4,000 in United States on PositoAI, with a Positivity Score of 17,825.

NasdaqCM: VBIO · Healthcare

Positivity Index

#5,295 / 6,774

Global

#2,854 / 4,000

United States

Positivity Score

17,825

Rank→

PosiRed: 1 active red flag (highest severity 6/10) View flag history →

PosiRed · red flag

Stock exchange listing-rule deficiency notice (8-K Item 3.01)

The company reported in a Form 8-K (Item 3.01) filed on 20 Mar 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.

More details →

Valion Bio, Inc. — Overview & Financial Snapshot

Valion Bio, Inc. (NasdaqCM: VBIO) is a Healthcare company, ranked #5,295 of 6,774 companies globally and #2,854 of 4,000 in United States on PositoAI, with a Positivity Score of 17,825. Its market capitalisation is ₹17.57 Cr ($1.86M), P/E ratio is -0.0 and P/B ratio is 0.44. It currently has 1 active red flag (PosiRed) and no yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →